UPURS Trial for Patient-centered Management of Symptomatic Obstructing Stones

Sponsor
University of California, San Francisco (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05715086
Collaborator
(none)
100
1
2
15
6.6

Study Details

Study Description

Brief Summary

A prospective, non-blinded, randomized controlled trial studying the management of symptomatic ureteral stones. This study will compare upfront ureteroscopy vs observation and delayed intervention for patients presenting to the emergency department with a symptomatic ureteral stone.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ureteroscopy
N/A

Detailed Description

Management of symptomatic ureteral stones is variable across the United States due to a lack of clear, patient-centered guidelines. For patients who do not meet criteria for emergent stenting, the decision to recommend upfront definitive treatment (ureteroscopy, ESWL) or medical expulsion therapy is influenced by factors such as practice setting, insurance status, and day of the week. This has resulted in health disparities and delays in care that disproportionately affect vulnerable patient populations.

For patients presenting to the emergency department with a symptomatic ureteral stone investigators will randomize into Group A: Upfront Ureteroscopy or Group B: Delayed intervention and observation. Both arms are considered standard of care for patients presenting with the above diagnosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A prospective, non-blinded, randomized controlled trial with two study arms.A prospective, non-blinded, randomized controlled trial with two study arms.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Upfront vs Postponed Ureteroscopy (UPURS) Trial for Patient-centered Management of Symptomatic Obstructing Stones
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group A (Upfront ureteroscopy)

Procedure: Ureteroscopy
Upfront ureteroscopy

No Intervention: Group B (Observation/delayed ureteroscopy)

Outcome Measures

Primary Outcome Measures

  1. Pain Score [3 months]

    Measure on a scale of 1-10, with zero indicating no pain and 10 indicating the worst pain.

  2. Anxiety Score [3 months]

    Measure on a scale of 1-10, the score ranges from 0-10, with zero indicating no anxiety and 10 indicating the worst anxiety.

Secondary Outcome Measures

  1. Hospital visit length [3 months]

    Measured in number of days

Other Outcome Measures

  1. Days of work lost [3 months]

    Measured in number of days

  2. Hospital visits [3 months]

    Measure in number of times

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Presenting to the Emergency Department (ED)

  • Adult (> 18 yo)

  • ≥5mm ureteral stone diagnosed on CT scan

  • Presence of symptoms (pain, nausea, vomiting, hematuria)

Exclusion Criteria:
  • Strict indication for stent

  • Stone burden not amenable to Ureteroscopy (URS)

  • Dirty urine analysis (UA) or positive urine culture (UCx)

  • Transplant kidney

  • Presence of conduit

  • Comorbidities not optimized for surgery

  • Strong preference for surgery or observation

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, San Francisco San Francisco California United States 94143

Sponsors and Collaborators

  • University of California, San Francisco

Investigators

  • Principal Investigator: Thomas Chi, MD, University of California, San Francisco

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT05715086
Other Study ID Numbers:
  • 22-37665
First Posted:
Feb 6, 2023
Last Update Posted:
Feb 6, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of California, San Francisco
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 6, 2023